SEC Form SC 13G filed by Alkermes plc

11/4/24 10:58:17 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ALKS alert in real time by email

SC 13G 1 UnitedStates_13G__AlkermesPL.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 14)* (Name of Issuer) Alkermes PLC (Title of Class of Securities) Common Stock (CUSIP Number) G01767105 (Date of Event Which Requires Filing of this Statement) September 30, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: X Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, an* d for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of * the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. G01767105 (1) Names of reporting persons The Vanguard Group (2) Check the appropriate box if a member of a group (a) (see instructions) (b) X (3) SEC use only (4) Citizenship or place of organization Pennsylvania Number of shares beneficially owned by each reporting person with: (5) Sole voting power 0 (6) Shared voting power 322,244 (7) Sole dispositive power 18,461,942 (8) Shared dispositive power 509,695 (9) Aggregate amount beneficially owned by each reporting person 18,971,637 (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions) (11) Percent of class represented by amount in Row (9) 11.52% (12) Type of reporting person (see instructions) IA Item 1(a) Name of issuer: Alkermes PLC Item 1(b) Address of issuer's principal executive offices: Connaught House 1 Burlington Road Dublin 4, D04 C5Y6 Items 2(a)-2(c). Name, Address Of principal business office, and Citizenship of* persons filing: The Vanguard Group - 23-1945930 100 Vanguard Blvd. Malvern, PA 19355 2(d) Title of class of securities: Common Stock 2(e) CUSIP Number: G01767105 Item 3. This statement is being filed pursuant to Rule 13d-1. An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E). Item 4. Ownership As of the close of business on September 30, 2024: (a) Aggregate amount beneficially owned: 18,971,637 (b) Percent of class: 11.52% (c) Number of shares as to which person has: 1. The Vanguard Group (a) Amount beneficially owned: 18,971,637 (b) Percent of class: 11.52% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 322,244 (iii) Sole power to dispose or to direct the disposition of: 18,461,942 (iv) Shared power to dispose or to direct the disposition of: 509,695 Item 5.Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following . Item 6. Ownership of More than 5 Percent on Behalf of Another Person. The Vanguard Group, Inc.'s clients, including investment companies registered u* nder the Investment Company Act of 1940 and other managed accounts, have the ri* ght to receive or the power to direct the receipt of dividends from, or the pro* ceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5* %. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being

Get the next $ALKS alert in real time by email

Recent Analyst Ratings for

$ALKS

Date	Price Target	Rating	Analyst
6/17/2025	$42.00	Neutral → Buy	UBS
5/28/2025	$45.00	Buy	Needham
3/13/2025	$40.00	Sector Perform	RBC Capital Mkts
3/4/2025	$21.00 → $38.00	Sell → Neutral	UBS
2/11/2025	$40.00	Buy	Deutsche Bank
11/5/2024	$25.00 → $36.00	Hold → Buy	Stifel
6/17/2024	$34.00	Buy	TD Cowen
3/19/2024	$37.00	Outperform	Robert W. Baird

More analyst ratings

SEC Form SC 13G filed by Alkermes plc

Chat with this insight

Recent Analyst Ratings for
$ALKS

$ALKS
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SVP, Chief Commercial Officer Nichols Christian Todd sold $210,143 worth of Ordinary Shares (6,667 units at $31.52), decreasing direct ownership by 7% to 86,208 units (SEC Form 4)

Director Wright Christopher I converted options into 3,301 units of Ordinary Shares and covered exercise/tax liability with 793 units of Ordinary Shares, increasing direct ownership by 12% to 23,013 units (SEC Form 4)

Director Wright Christopher I covered exercise/tax liability with 1,924 units of Ordinary Shares and converted options into 8,013 units of Ordinary Shares, increasing direct ownership by 42% to 20,505 units (SEC Form 4)

$ALKS
SEC Filings

Alkermes plc filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

SEC Form SCHEDULE 13G filed by Alkermes plc

SEC Form DEFA14A filed by Alkermes plc

$ALKS
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Alkermes Plc upgraded by UBS with a new price target

Needham initiated coverage on Alkermes Plc with a new price target

RBC Capital Mkts initiated coverage on Alkermes Plc with a new price target

$ALKS
Press Releases

Fastest customizable press release news feed in the world

Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences

Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025

$ALKS
Leadership Updates

Live Leadership Updates

Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors

Uber Technologies, Jabil and Builders FirstSource Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc

$ALKS
Financials

Live finance-specific insights

Alkermes plc Reports First Quarter 2025 Financial Results

Alkermes to Report First Quarter Financial Results on May 1, 2025

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025

$ALKS
Large Ownership Changes

This live feed shows all institutional transactions in real time.